BiotechTube

Radium-223 dichloride (Xofigo, BAY88-8223)

Pre-clinicalCompleted
2 views this week 0 watching💤 Quiet
Interest: 23/100
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Castration-resistant Prostate Cancer

Conditions

Castration-resistant Prostate Cancer

Trial Timeline

Jul 7, 2020 → Apr 29, 2024

NCT ID
NCT04232761

About Radium-223 dichloride (Xofigo, BAY88-8223)

Radium-223 dichloride (Xofigo, BAY88-8223) is a pre-clinical stage product being developed by Bayer for Castration-resistant Prostate Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT04232761. Target conditions include Castration-resistant Prostate Cancer.

What happened to similar drugs?

4 of 20 similar drugs in Castration-resistant Prostate Cancer were approved

Approved (4) Terminated (1) Active (15)
✅EnzalutamideAstellas PharmaApproved
✅EnzalutamideAstellas PharmaApproved
🔄Enzalutamide + PlaceboAstellas PharmaPhase 3
🔄Enzalutamide + PlaceboAstellas PharmaPhase 3
🔄[Lu-177]-PNT2002 + Abiraterone + EnzalutamideEli LillyPhase 3
🔄Fuzuloparib , Abiraterone acetate and Prednisone + Fuzuloparib Placebo， Abiraterone acetate and PrednisoneJiangsu Hengrui MedicinePhase 3
🔄HRS-4357 injection + Enzalutamide；AbirateroneJiangsu Hengrui MedicinePhase 3

Hype Score Breakdown

Clinical
3
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (12)

NCT IDPhaseStatus
NCT05301062Pre-clinicalTerminated
NCT04521361Phase 1Completed
NCT04516161Pre-clinicalCompleted
NCT04232761Pre-clinicalCompleted
NCT04281147Pre-clinicalCompleted
NCT03315260Pre-clinicalCompleted
NCT02518698Pre-clinicalCompleted
NCT02141438Pre-clinicalCompleted
NCT02023697Phase 2Completed
NCT01934790Phase 1/2Completed
NCT01929655Phase 2Completed
NCT01810770Phase 3Completed

Competing Products

20 competing products in Castration-resistant Prostate Cancer

See all competitors
ProductCompanyStageHype Score
SRF617 + etrumadenant + zimberelimabCoherus BioSciencesPhase 2
17
Docetaxel + Ifinatamab Deruxtecan + MK-5684 + Abiraterone + Enzalutamide + Rescue MedicationDaiichi SankyoPhase 1/2
39
Valemetostat + DarolutamideDaiichi SankyoPhase 1
36
EnzalutamideAstellas PharmaPhase 2
35
enzalutamide + abiraterone acetate + prednisoneAstellas PharmaPhase 2
35
Crizotinib + EnzalutamideAstellas PharmaPhase 1
29
EnzalutamideAstellas PharmaPhase 2
35
Lu-PSMA + EnzalutamideAstellas PharmaPhase 2
31
EnzalutamideAstellas PharmaApproved
43
enzalutamideAstellas PharmaPre-clinical
26
Enzalutamide + FlutamideAstellas PharmaPhase 2
35
Enzalutamide + Abiraterone acetateAstellas PharmaPre-clinical
26
EnzalutamideAstellas PharmaApproved
43
EnzalutamideAstellas PharmaPhase 2
35
MDV3100Astellas PharmaPre-clinical
26
Enzalutamide + PlaceboAstellas PharmaPhase 3
40
ZEN003694 + EnzalutamideAstellas PharmaPhase 2
42
Enfortumab vedotinAstellas PharmaPhase 2
39
EnzalutamideAstellas PharmaPhase 2
27
EnzalutamideAstellas PharmaPhase 2
35